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Abstract Most of the known cellular substrates of the ubiquitin
system are short-lived growth regulators and transcriptional
activators. Very few enzymes involved in intermediary metabo-
lism have been shown to be targeted by the system. In a
reconstituted cell-free system, we show that tyrosine amino-
transferase (TAT), a key enzyme involved in amino acid
metabolism, is conjugated and degraded in an ATP- and
ubiquitin-dependent manner. Degradation of ubiquitin^TAT
adducts requires, in addition to the 26S proteasome, a novel,
yet unidentified, factor. TAT can be protected from degradation
by association with its coenzyme pyridoxal phosphate. To
examine the potential role of the ubiquitin system in regulating
the stability of the enzyme in vivo, we show that cell extracts
derived from livers of animals in which TAT was induced, display
a corollary increase in the formation of specific TAT^ubiquitin
adducts.
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1. Introduction
Tyrosine aminotransferase (TAT; EC 2.6.1.5) is the rate-
limiting enzyme in tyrosine catabolism. It prevents accumula-
tion of toxic levels of tyrosine and provides ketogenic and
gluconeogenetic substrates when supply of glucose to cells is
limited and amino acids serve as a major source of energy.
The enzyme, a homodimer composed of two identical 454
amino acid residue polypeptide chains, is expressed only in
the liver and is extremely unstable with a half-life of 1^2 h [1].
Activity of TAT is highly regulated by changes in its rate of
synthesis and degradation. The enzyme is strongly induced by
glucocorticoids that increase the rate of transcription [2].
cAMP also increases TAT activity by increasing the level of
the transcript. However, cAMP can partially induce the en-
zyme under conditions of complete inhibition of mRNA syn-
thesis, suggesting that its e¡ect is mediated also by a post-
transcriptional mechanism, such as stabilization of the mRNA
or inhibition of degradation [3]. Insulin, that also induces
activity of the enzyme, has only a small and transient e¡ect
on the level of TAT transcript, and appears to act via a
post-transcriptional mechanism. It exerts its full e¡ect in the
presence of 5,6-dichloro-1-L-D-ribofuranosylbenzimidazole
(DRB), a potent inhibitor of mRNA synthesis, conditions
under which the e¡ect of glucocorticoids is completely
blocked [3]. Spencer and colleagues have shown that insulin
selectively slows the degradation rate of the enzyme [4]. De-
tailed structural analysis revealed that short sequences near
both ends of TAT are necessary for its rapid degradation.
The required basic sequence near the N-terminus (33-
RKKGRKAR-40) contains three Lys residues that can poten-
tially serve as ubiquitination sites. The second sequence (450-
EECDK-454) is located at the very C-terminus of the mole-
cule and is part of a PEST (Pro, Glu, Ser, Thr) domain im-
plicated in targeting short-lived proteins for degradation [5].
Another factor that probably plays a role in determining the
stability of the enzyme is its coenzyme, pyridoxal phosphate
(PLP). The presence of PLP during puri¢cation of the enzyme
is essential for the maintenance of its activity [6]. It has been
shown that the relative rate of PLP dissociation from di¡erent
transaminases aligns with the shortness of the half-lives of
these enzymes [7]. In all these studies, the cellular system
and the mechanism(s) involved in the degradation of TAT
have not been identi¢ed, although it has been recently shown
that many short-lived and regulatory cellular proteins are tar-
geted via the ubiquitin pathway.
The ubiquitin-dependent pathway plays an important role
in the degradation of many short-lived regulatory proteins
such as cyclins and CDK, tumor suppressors, oncoproteins,
and transcriptional activators and their inhibitors. Degrada-
tion of a protein via the ubiquitin system involves two suc-
cessive steps: conjugation of multiple molecules of ubiquitin
to the target protein and degradation of the tagged molecule
by the 26S proteasome complex. Selection of proteins for
degradation can be mediated via primary (constitutive) or
secondary signals such as post-translational modi¢cations or
association with ancillary proteins or cofactors (reviewed in
refs. [8] and [9]). So far, only a single enzyme, fructose-1,6-
biphosphatase, that is involved intermediary metabolism, has
been described as a substrate of the ubiquitin system [10,11].
This cytoplasmic key gluconeogenetic enzyme is subject to
catabolite inactivation in the yeast S. cerevisiae. Addition of
glucose to yeast grown on non-fermentable carbon source
leads to rapid degradation of the enzyme that follows phos-
phorylation-dependent inactivation of its catalytic activity.
Here we show that TAT is degraded by the ubiquitin sys-
tem in vitro and is protected by its coenzyme PLP. In liver
cells, there is a strong correlation between the level of TAT
and the ability of the cells to catalyze formation of TAT^
ubiquitin adducts that serve as proteolytic intermediates.
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2. Materials and methods
2.1. Materials
Sepharose-immobilized protein G was from Pharmacia. Antibodies
were from Bio Makor. Materials for SDS-PAGE were from Bio-Rad.
Dexamethasone phosphate, PLP, L-Tyr, K-KG, L-Glu, K-LA, and ¢ne
chemicals and bu¡ers were purchased from Sigma or Boehringer.
DEAE (DE52) and CM (CM52) cellulose were from Whatman. Ni-
trocellulose paper was from Schleicher and Scheull. All other chem-
icals were of high analytical grade.
2.2. Methods
2.2.1. Preparation of puri¢ed TAT and anti-TAT serum. TAT was
puri¢ed from rat livers as described [6]. To remove PLP from the
enzyme and the proteolytic extracts, samples were dialysed against a
bu¡er containing 125 mM KPi (pH 7.6), 2 mM L-glutamate, and
1 mM DTT. Anti-TAT serum was a gift from Dr. Christopher Pog-
son (Wellcome Research Laboratories, Kent, UK). Immunoglobulins
were further puri¢ed by (NH
4
)
2
SO
4
(40%) precipitation (40% satura-
tion).
2.2.2. Assay of TAT activity. TAT activity was assayed as de-
scribed [12]. To monitor activity following proteolysis in reticulocyte
lysate, it was necessary to remove hemoglobin that also absorbs at 331
nm, the wavelength at which the TAT reaction product, p-hydroxy-
phenylpyruvate, absorbs. Following incubation, 500 Wl of 50% CM
cellulose slurry in a bu¡er containing 50 mM MES (pH 6.35), 1 mg/ml
BSA, 1 mM EDTA, 1 mM DTT, and 0.1 mM PLP were added to the
50 Wl reaction mixture and activity was determined in the supernatant.
Degradation was calculated from the decrease in activity as compared
to a reaction mixture that did not contain ATP or that was incubated
on ice.
2.2.3. Determination and iodination of proteins. Protein was deter-
mined using the Bradford method [13]. Proteins were iodinated using
the chloramine-T method as described [14]
2.2.4. Preparation and fractionation of rabbit reticulocytes lysate.
Lysate was prepared from reticulocyte-rich rabbit blood and was re-
solved by anion exchange chromatography over DEAE-cellulose into
unadsorbed material (Fraction I) and high-salt eluate (Fraction II) as
described [14].
2.2.5. Conjugation and degradation assays. Degradation and con-
jugation assays of TAT were performed essentially as described [15,16]
with slight modi¢cations. Reaction mixtures contained in a ¢nal vol-
ume of 50 Wl : 35 Wl reticulocyte lysate (or PLP-depleted lysate; see
above) or 200 Wg protein of Fraction II. When indicated, Fraction I
(25 Wl) and/or ubiquitin (5 Wg) were added. Reaction mixtures were
resolved via SDS-PAGE (10%), and the proteins blotted onto Nitro-
cellulose paper as described [17]. Following blocking of non-speci¢c
binding sites, the paper was incubated successively at 4³C in the pres-
ence of sheep anti-TAT or sheep pre-immune IgG (50 Wg/ml), rabbit
anti-sheep IgG (10 Wg/ml), and HRP-conjugated goat anti-rabbit IgG
(1 unit HRP/ml). Proteins were visualized using the DAB [18] or the
ECL methods. Degradation of
125
I-labeled proteins was monitored by
measuring the release of radioactivity into TCA-soluble fraction [14].
To demonstrate a correlation between the level of the enzyme in
vivo and the level the corresponding conjugating activity, labeled
ubiquitin was incubated in the presence of rat liver cytosolic extracts
in which TAT was induced by starvation and dexamethasone [6].
Reaction mixtures were similar to those described above except that
Fraction II derived from cytosolic extracts was used as a source for
the conjugating enzymes, TAT was endogenous, and the reaction
contained instead of unlabeled ubiquitin
125
I-labeled ubiquitin (V1
Wg;V1 000 000 cpm). Following incubation, the reaction mixture was
brought to 0.5 ml by the addition of a bu¡er containing 50 mM Tris-
HCl (pH 8.0), 5 mM EDTA (pH 8.0), 150 mM NaCl, 1% Triton X-
100, 2 mM PMSF, and 20 Wg/ml aprotinin. Pre-immune sheep IgG
was added (25 Wg; preclearing) and removed by the addition of im-
mobilized Protein G (10 Wl of 50% suspension). Speci¢c anti-TAT IgG
or pre-immune sheep IgG (25 Wg) were added, and the IgG was
adsorbed onto immobilized Protein G. The beads were collected
and washed. Following addition of sample bu¡er, the immunopreci-
pitate was resolved via 10% SDS-PAGE, and the gel dried and ex-
posed to a ¢lm.
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Fig. 1. A: Time- and ATP-dependent decrease in TAT activity. TAT (70 ng) was incubated in a reaction mixture containing rabbit reticulocyte
lysate in the presence or absence of ATP for the indicated time periods and the changes in activity of the enzyme were monitored as described
under Section 2. Results are expressed as decrease in activity. B: Time- and ATP-dependent degradation of TAT. 21 ng TAT was incubated in
reticulocyte lysate and degradation was monitored via Western blot analysis following SDS-PAGE as described under Section 2. The resolved
reaction contained 3.5 ng of the enzyme. Lane 1: 3.5 ng of untreated, native TAT. Lane 2: reaction mixture incubated in the absence of TAT.
Lanes 3^6 and 7^10: reaction mixtures incubated in the absence or presence of ATP, respectively, for 0, 30, 60, and 120 min. MW markers are
indicated. Ori., origin of gel.
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2.2.6. Preparation of rat liver extracts. Liver extracts that contain
all the conjugating enzymes were prepared from untreated or starved
and dexamethasone-treated rats as described [6]. Following centrifu-
gations at 9000Ug for 15 min and at 100 000Ug for 60 min, the
supernatant was collected and frozen at 370³C.
3. Results
3.1. Puri¢ed TAT and assay of activity
Active TAT was puri¢ed to almost homogeneity (not
shown). To measure enzyme activity in reticulocyte lysates,
it was necessary to remove hemoglobin. That because hemo-
globin and the enzymatic reaction product of TAT, p-hy-
droxyphenylpyruvate, absorb strongly at 331 nm. We utilized
the di¡erence in the pI's between the two proteins to adsorb
hemoglobin to the cation exchange resin CM cellulose at pH
6.35. At this pH hemoglobin adsorbs whereas more than 85%
of the activity of TAT remains soluble (not shown).
3.2. Degradation of TAT in rabbit reticulocyte lysate requires
ATP
In order to establish a cell-free system that degrades TAT
and to study the potential role of the ubiquitin pathway in the
process, we monitored the disappearance of TAT activity in
rabbit reticulocyte lysate. Since activation of ubiquitin as well
as the assembly and activity of the 26S proteasome require
ATP, it was important to monitor the requirement for this
nucleotide in the cell-free system. As can be seen in Fig. 1A,
disappearance of TAT is completely dependent upon addition
of the nucleotide. ADP and GTP did not have any e¡ect (not
shown). To rule out the possibility that the incubation in the
presence of ATP leads to inactivation of the enzyme and to
demonstrate that the protein molecule is completely degraded,
we monitored the fate of TAT by Western blot analysis. As
can be seen in Fig. 1B, addition of ATP leads to a time-
dependent disappearance of the antigen (lanes 7^10). In con-
trast, depletion of ATP stabilizes the enzyme (lanes 3^6). In-
terestingly, degradation of TAT does not lead to the forma-
tion of intermediate products, and proteolysis proceeds to
completion.
3.3. Ubiquitin- and ATP-dependent conjugation of TAT
To demonstrate the intermediacy of ubiquitin conjugation
in TAT proteolysis, we monitored the ability of the molecule
to covalently tag TAT. As can be seen in Fig. 2, addition of
increasing amounts of ubiquitin lead to the formation of high
MW ubiquitin-TAT adducts that were not formed in the ab-
sence of energy.
3.4. ATP-, ubiquitin-, and Fraction I-dependent degradation of
TAT
To examine whether ubiquitin can promote degradation of
TAT, we incubated the enzyme in the presence of Fraction II.
As can be seen in Table 1, addition of ubiquitin did not a¡ect
the stability of the enzyme. Thus, whereas ubiquitin can gen-
erate high MW adducts with TAT, these adducts cannot be
degraded in Fraction II that contains the 26S proteasome
complex. In our previous studies, we have shown that Frac-
tion I contains the protein synthesis elongation factor EF-1K
that is required for the degradation of certain N-K-acetylated
proteins [19]. EF-1K is not required for the conjugation of
these proteins, but rather for their degradation by the 26S
proteasome. It should be noted that the N-terminal residue
of TAT is acetylated [20]. Therefore, we set to examine the
e¡ect of Fraction I on the degradation of TAT. As can be
seen in Table 1, addition of Fraction I stimulates the degra-
dation of TAT signi¢cantly (V3-fold). Addition of puri¢ed
EF-1K did not have any e¡ect (not shown), suggesting that a
novel, yet unidenti¢ed factor, is involved in proteolysis of
TAT. We monitored the e¡ect of Fraction I on the fate of
the protein moiety of TAT. As can be seen in Fig. 3, addition
of ubiquitin to Fraction II leads to formation of conjugates,
but not to disappearance of the enzyme molecule (lane 6). In
contrast, when Fraction I is also added, TAT and its ubiquitin
adducts disappear (lane 9).
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Fig. 2. Ubiquitin- and ATP-dependent conjugation of TAT. 70 ng
of TAT was incubated in the presence of Fraction II in the absence
(lanes 1^3) or presence (lanes 4^8) of ATP. Ubiquitin was added at
0 (lanes 1 and 4), 2 (lane 5) 4 (lanes 2 and 6) 8 (lane 7) and 16
(lanes 3 and 8) Wg. Reaction mixtures (a portion containing 24 ng)
were resolved and proteins visualized as described in the legend to
Fig. 2. MW markers are indicated. Ori., origin of gel.
Table 1
ATP-, ubiquitin- and Fraction I-dependent degradation of TAT in the presence of rabbit reticulocyte Fraction II
Experimental conditions Fraction II Fraction II+ubiquitin Fraction II+ubiquitin+Fraction I
3ATP 2.4 3.1 2.9
+ATP 4.2 8.6 24.5
Net ATP 1.8 5.5 21.6
Degradation of TAT was monitored in the di¡erent reaction mixtures as described under Section 2.
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3.5. E¡ect of PLP on the degradation of TAT
Several lines of evidence indicate that the association be-
tween TAT and its coenzyme PLP, protects the enzyme from
proteolysis (see in Section 1). To test the e¡ect of PLP ubiq-
uitin-mediated degradation of TAT, we depleted PLP from
the TAT preparation as well as from the proteolytic extract.
As can be seen in Fig. 4A, PLP speci¢cally protects TAT, but
does not have any e¡ect on the degradation of other proteins
(BSA, K-LA, and lysozyme) that do not associate with this
cofactor. To demonstrate that the absence of PLP does not
a¡ect only the activity of the enzyme, we followed the e¡ect of
the cofactor on the TAT molecule. As can be seen in Fig. 4B,
PLP-depleted TAT disappears completely when incubated in
the absence of PLP. In contrast, addition of PLP protects the
enzyme from degradation (compare lanes 3 and 6). Since the
TAT preparation and the proteolytic lysates contain a small
amount of PLP (¢nal concentration in the reaction mixture is
V0.5 WM), it is clear why the degradation of the non-depleted
enzyme in the untreated lysate is not complete (Fig. 1B, lane
10).
3.6. Formation of TAT^ubiquitin conjugates in the liver is
proportional to the level of the enzyme
To examine the relationship between the level of the enzyme
in the liver and the rate of formation of ubiquitin conjugates
that serve as proteolytic intermediates, we followed the for-
mation of these adducts in untreated livers and in livers in
which the enzyme was induced (10^30 fold) following starva-
tion and administration of dexamethasone. Labeled ubiquitin
was incubated in the presence of ubiquitin-depleted liver ex-
tract and speci¢c TAT conjugates were precipitated using
anti-TAT antibody. As can be seen in Fig. 5, formation of
speci¢c conjugates is signi¢cantly higher in the extract derived
from treated animals (compare lanes 3 and 4). Two independ-
ent lines of experimental evidence indicate that the high MW
derivatives are indeed ubiquitin^TAT adducts. (1) They are
formed only in the presence of ATP-Q-S (compare lanes 1 and
2 to lanes 3 and 4), and (2) preimmune serum fails to precip-
itate them (compare lanes 3 and 4 to lanes 7 and 8). To rule
out the possibility that the treatment of the rats a¡ects ubiq-
uitin conjugation to the general population of proteins, we
incubated labeled ubiquitin with extracts of livers derived
from untreated, starved, and starved and dexamethasone-
treated rats. Quantitative analysis reveals that there is no dif-
ference in the conjugation of ubiquitin to endogenous proteins
in all three extracts (not shown).
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Fig. 4. A: E¡ect of pyridoxal phosphate on the degradation of na-
tive TAT (F), and
125
I-labeled BSA (b), K-LA (R) and lysozyme
(O). Degradation of TAT and the labeled proteins was monitored
in a PLP-depleted reticulocyte lysate in the presence of the indicated
amounts of PLP as described under Section 2. 100% degradation is
the net ATP-dependent degradation. B: E¡ect of pyridoxal phos-
phate on the degradation of native TAT. 21 ng apo-TAT was incu-
bated in the presence of TAT-depleted reticulocyte lysate in the ab-
sence (lanes 1^3) or presence (lanes 4^6) of PLP (0.5 mM), and
degradation was monitored as described in the legend to Fig. 1B.
Fig. 3. E¡ect of Fraction I on the degradation of TAT and TAT
conjugates. Reaction mixtures containing 21 ng TAT were incubated
and resolved, and proteins visualized as described in the legend to
Fig. 2. Lanes 1^3: reactions carried out in the presence of Fraction
II. Lanes 4^6: as in Lanes 1^3, but in the presence of 5 Wg ubiqui-
tin. Lanes 7^9: as in Lanes 4^6, but in the presence of 25 Wl Frac-
tion I. Reactions were incubated in the absence (lanes 1, 2, 4, 5, 7
and 8) or presence (lanes 3, 6 and 9) of ATP. Reactions resolved in
lanes 1, 4, and 7 were incubated on ice, whereas reactions resolved
in lanes 2, 3, 5, 6, 8, and 9 were incubated at 37³C for 2 h. Conj.,
conjugates; Df., dye front; Ori., origin of gel.
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4. Discussion
We have shown that the degradation of native TAT in vitro
is mediated by the ubiquitin proteolytic system and the en-
zyme can be protected by its coenzyme, PLP. In cell extracts,
the rate of formation of conjugates of ubiquitin with native
endogenous TAT is proportional to the steady-state level of
the enzyme, suggesting that TAT is targeted by the ubiquitin
system in vivo as well.
To reconstitute activity, it was necessary to add Fraction I
that contains a novel, yet unidenti¢ed factor required for the
degradation of conjugates. This factor is distinct from EF-1K
required for the degradation of conjugates of several N-K-
acetylated proteins [19]. What can be the role of the factor
in Fraction I? It can be, for example, an isopeptidase that
trims polyubiquitin chains from the conjugates and thus ren-
dering them susceptible to the activity of the 26S proteasome.
Without this activity, the conjugates are not recognized by the
protease complex. Recent evidence indicates that Fraction I
indeed contains several isopeptidatic activities (unpublished
results). This factor can also be a subunit or an activator of
the protease that is involved in degradation of speci¢c subset
of proteins. Several activators of the 20S protease, PA28 for
example, have been described recently [21], however, their
function has remained elusive.
It has been suggested that many enzymes are protected by
their co-factors; however, a direct role for a co-factor in the
stabilization of the core protein of an enzyme from degrada-
tion by a speci¢c cellular proteolytic system has not been
demonstrated. Here we demonstrate that PLP speci¢cally pro-
tects TAT from ubiquitin-mediated degradation. It is possible
that the co-factor changes the three-dimensional structure of
the enzyme and limit the accessibility of the ubiquitin^TAT
ligase (E3) to a speci¢c recognition/binding site. Alternatively,
E3 binds to the protein, but the E2 cannot transfer ubiquitin
to a sterically hidden speci¢c Lys residue. Interestingly, PLP
binds to a speci¢c Lys residue [20], and it will be interesting to
study whether this residue serves as a ubiquitination site.
Also, it is possible that PLP sterically hinders the Lys residues
in the N-terminal domain that is involved in targeting TAT
for degradation (see in Section 1). It should be noted, how-
ever, that the physiological signi¢cance of PLP protection is
not clear yet. Protection occurs at concentrations that exceed
the K
d
. Also, vitamin B6 (the precursor of PLP) de¢ciency
does not alter the stability of the enzyme. On the other
hand, a signi¢cant proportion of TAT is always found in
the cell in its apo form, devoid of its co-factor [22]. Also, as
mentioned in Section 1, there are strong in vitro as well as in
vivo correlations between the association parameters of trans-
aminases with PLP and their stabilities. Thus, it appears the
factors that a¡ect the association of TAT and PLP and the
role of PLP in determining the stability of the enzyme in the
cell are complex and need further investigation.
An important, yet unresolved problem is whether the activ-
ity of the ubiquitin system is regulated and the rate of degra-
dation is in£uenced by changing physiological conditions. In
any event, regulation of TAT by degradation is important, as
this is the only way to remove the enzyme following induction
of its synthesis.
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